Circuit Clinical partners to shape data to drive discovery

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/metamorworks)
(Image: Getty/metamorworks)

Related tags: Drug discovery, Drug development, Drug development process, Circuit Clinical, Clinical data, Data management, patient engagement, Data

Circuit Clinical and CUBRC partner to enhance patient data for drug discovery and development services through machine learning platforms and AI.

Integrated research organization (IRO), Circuit Clinical’s agreement with CUBRC expands its discovery services. Per the agreement, Circuit Clinical’s physician network, and patient engagement platform, TrialScout, will be combined with CUBRC’s analytical software tools for analysis.

CUBRC, an independent not-for-profit research and development company will provide Circuit Clinical access to its Heartwood Analytics machine learning platform for drug discovery.

According to Irfan Khan, CEO of Circuit Clinical, its existing platforms enable the company to directly work with patients who may donate genomic and health data in a transparent matter.

Khan told us that this partnership is designed to extend the company’s reach into early-stage drug discovery by providing the ability to analyze the deep electronic medical records and genomic data it collects for sponsors and academic research partners.

“The partnership with CUBRC now gives Circuit Clinical the ability to transform this data to identify important signals that can assist in drug discovery and public health. The potential for drug development at this scale is considerable,”​ Khan added.

CUBRC’s CIO and senior VP of Information Exploitation Sector, Mike Moskal the partnership will enable the company to apply its machine learning and artificial intelligence (AI) platforms to provide high-confidence predictions to improve efficacy and individual patient response.

The use of CUBRC’s AI in this partnership has great potential to identify the effect of a person’s genetic code on their health, Khan told us.

He added, “Better data leads to better information, but above all is patient transparency and ownership - if we focus on creating new value for people who willingly share their data to drive discovery - the potential is incredible."

The IRO will also work with CUBRC to work on projects for the National Institute of Health (NIH) and the US Department of Defense (DoD).

Related news

Show more

Related products

show more

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars